Research Spotlight - October 2020

The October edition of Research Spotlight features 10 recent research discoveries from scientists whom Boster has served.

This month’s research publications examine treatments and mechanisms for cancers such as breast cancer, colitis-associated cancer, and ovarian cancer. Scientists also propose stem cell derived biomimetic vesicles for versatile and effective targeted delivery. In addition, researchers investigate how dihydroartemisinin (DHA) can ameliorate psoriatic skin inflammation.

Scroll down to learn more about these new scientific discoveries.

GSH Depletion Liposome Adjuvant for Augmenting the Photothermal Immunotherapy of Breast Cancer

Authors: Zhou, Z., Wu, H., Yang, R., Xu, A., Zhang, Q., Dong, J., Qian, C., & Sun, M.
Journal: Science Advances

The high redox level of tumor microenvironment inhibits the oxidation treatment and the immune response. Here, we innovatively develop maleimide liposome (ML) adjuvants to promote immunogenic cell death (ICD) induction and dendritic cells (DCs) maturation by glutathione (GSH) depletion for augmenting the photothermal immunotherapy...

Read More

Cited Boster Product(s): Mouse TNF Alpha ELISA Kit PicoKine™ (EK0527); Mouse IFN Gamma / IFNG / Interferon Gamma ELISA Kit PicoKine™ (EK0375); Mouse IL-12(P40) ELISA Kit PicoKine™ (EK0932)

Zika Virus NS2A Protein Induces the Degradation of KPNA2 (Karyopherin Subunit Alpha 2) via Chaperone-mediated Autophagy

Authors: He, J., Yang, L., Chang, P., Yang, S., Lin, S., Tang, Q., Wang, X, & Zhang, Y.
Journal: Autophagy

KPNA2/importin-alpha1 (karyopherin subunit alpha 2) is the primary nucleocytoplasmic transporter for some transcription factors to activate cellular proliferation and differentiation. Aberrant increase of KPNA2 level is identified as a prognostic marker in a variety of cancers. Yet, the turnover mechanism of KPNA2 remains unknown...

Read More

Cited Boster Product(s): Anti-LAMP2a Rabbit Monoclonal Antibody (M01573)

Engineering Stem Cell Derived Biomimetic Vesicles for Versatility and Effective Targeted Delivery

Authors: Wu, H., Jiang, X., Li, Y., Zhou, Y., Zhang, T., Zhi, P., & Gao, J.
Journal: Advanced Functional Materials

To date, only a few types of nanomedicines have been made available for clinical use even in the most common liposomal delivery systems, due to significant constraints, including poor targeting of specific cells, hindered penetration, and accelerated clearance. Various intricate designs have been generated and show improvements, while also bringing...

Read More

Cited Boster Product(s): BCA Protein Assay Kit (AR0146); Mouse IL-6 ELISA Kit PicoKine™ (EK0411); Mouse TNF Alpha ELISA Kit PicoKine™ (EK0527)

Exosome-derived miR-142-5p Remodels Lymphatic Vessels and Induces IDO to Promote Immune Privilege in the Tumour Microenvironment

Authors: Zhou, C., Zhang, Y., Yan, R., Huang, L., Mellow, A.L., Yang, Y., Chen, X...
Journal: Cell Death & Differentiation

Clinical response to immunotherapy is closely associated with the immunosuppressive tumour microenvironment (TME), and influenced by the dynamic interaction between tumour cells and lymphatic endothelial cells (LECs). Here, we show that high levels of miR-142-5p positively correlate with indoleamine 2,3-dioxygenase (IDO) expression...

Read More

Cited Boster Product(s): ISH Detection Kit (POD) (MK1030)

FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity

Authors: Kraman, M., Faroudi, M., Allen, N.L., Kmiecik, K., Gliddon, D., Seal, C...
Journal: Clinical Cancer Research

Purpose: Although programmed death-ligand 1 (PD-L1) antibody–based therapy has improved the outcome of patients with cancer, acquired resistance to these treatments limits their clinical efficacy. FS118 is a novel bispecific, tetravalent antibody (mAb2 ) against human lymphocyte activation gene-3 (LAG-3) and PD-L1 with the potential...

Read More

Cited Boster Product(s): Mouse PD-L1/B7-H1 ELISA Kit PicoKine™ (EK1450)

Dihydroartemisinin Ameliorates Psoriatic Skin Inflammation and Its Relapse by Diminishing CD8+ T-cell Memory in Wild-Type and Humanized Mice

Authors: Chen, Y., Yan, Y., Liu, H., Qiu, F., Liang, C.L., Zhang, Q., Huang, R.Y...
Journal: Theranostics

Conventional immunosuppressants cause side effects and do not prevent the recurrence of autoimmune diseases. Moreover, they may not inhibit autoimmunity mediated by pathogenic memory T-cells. Dihydroartemisinin (DHA) has been shown to regulate autoimmunity. However, it remains unknown whether DHA impacts psoriasis and its recurrence...

Read More

Cited Boster Product(s): Mouse IL15RA ELISA Kit PicoKine™ (EK1142); Mouse IL-17 ELISA Kit PicoKine™ (EK0431); Mouse IFN Gamma / IFNG / Interferon Gamma ELISA Kit PicoKine™ (EK0375); Mouse TNF Alpha ELISA Kit PicoKine™ (EK0527)

Targeting an Autocrine IL-6–SPINK1 Signaling Axis to Suppress Metastatic Spread in Ovarian Clear Cell Carcinoma

Authors: Mehner, C., Miller, E., Hockla, A., Coban, M., Weroha, S.J., Radisky, D.C...
Journal: Oncogene

A major clinical challenge of ovarian cancer is the development of malignant ascites accompanied by widespread peritoneal metastasis. In ovarian clear cell carcinoma (OCCC), a challenging subtype of ovarian cancer, this problem is compounded by near-universal primary chemoresistance; patients with advanced stage OCCC thus lack...

Read More

Cited Boster Product(s): Human SPINK1/TATI ELISA Kit PicoKine™ (EK1241)

Generation and Characterization of a New Resistance to Thyroid Hormone Mouse Model with Thyroid Hormone Receptor Alpha Gene Mutation

Authors: Liang, Y., Zhao, D., Wang, R., Dang, P., Xi, Y., Zhang, D., Wang, W...
Journal: Thyroid

Background In humans, Resistance to Thyroid Hormone (RTH) caused by mutations in the thyroid hormone receptor alpha (THRA) gene, RTHα, manifests as tissue-specific hypothyroidism and circulating thyroid hormone levels that exhibits hypothyroid-like clinical features. Before the identification of patients with RTHα, several Thrα1...

Read More

Cited Boster Product(s): Mouse IGF-1 ELISA Kit PicoKine™ (EK0378)

Arctigenin Disrupts NLRP3 Inflammasome Assembly in Colonic Macrophages via Downregulating Fatty Acid Oxidation to Prevent Colitis-associated Cancer

Authors: Qiao, S., Lv, C., Tao, Y., Miao, Y., Zhu, Y., Zhang, W., Sun, D., Yun, X...
Journal: Cancer Letters

Arctigenin, the major active constituent of Fructus Arctii, has been reported to inhibit the growth of various tumors and alleviate colitis. This study aimed to prove the protective effect of arctigenin on colitis-associated cancer (CAC) and explore its mechanisms. Orally administered arctigenin prevented the progression of colitis...

Read More

Cited Boster Product(s): Broad Spectrum Protease Inhibitor Cocktail (100x) (AR1182)

The lncRNA-GAS5/miR-221-3p/DKK2 Axis Modulates ABCB1-Mediated Adriamycin Resistance of Breast Cancer via the Wnt/b-Catenin Signaling Pathway

Authors: Chen, Z., Pan, T., Jiang, D., Jin, L., Geng, Y., Feng, X. Shen, A., & Zhang, L.
Journal: Molecular Therapy - Nucleic Acids

Drug resistance, including adriamycin (ADR)-based therapeutic resistance, is a crucial cause of chemotherapy failure in breast cancer treatment. Acquired chemoresistance has been identified to be closely associated with the overexpression of P-glycoprotein (P-gp/ABCB1). Long non-coding RNA (lncRNA) growth arrest-specific 5 (GAS5) can...

Read More

Cited Boster Product(s): BCA Protein Assay Kit (AR0146)